Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | CXCR2 | P25025 | 7/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CXCR4 | P61073 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21603842 | 0.88 | CXCR2 (0.61) | MAPTALDH1A1HPGDMAPK1KMT2A | |
| SCHEMBL3923739 | 0.84 | CXCR2 (0.70) | MAPTALDH1A1HPGDMAPK1KMT2A | |
| SCHEMBL21597110 | 0.83 | KDM4E (0.47) | MAPTALDH1A1HPGDMAPK1KMT2A | |
| SCHEMBL21597710 | 0.80 | KDM4E (0.69) | MAPTALDH1A1HPGDMAPK1KMT2A | |
| SCHEMBL21597578 | 0.79 | CNR2 (0.43) | MAPTALDH1A1HPGDMAPK1KMT2A | |
| SCHEMBL21597584 | 0.78 | ALDH1A1 (0.58) | MAPTALDH1A1HPGDMAPK1KMT2A | |
| SCHEMBL5451004 | 0.78 | MAPT (0.77) | MAPTALDH1A1HPGDKMT2APOLB | |
| SCHEMBL21597779 | 0.76 | KMT2A (0.59) | MAPTALDH1A1HPGDMAPK1KMT2A | |
| SCHEMBL21597480 | 0.75 | MAPT (0.60) | MAPTALDH1A1HPGDMAPK1KMT2A | |
| SCHEMBL5450569 | 0.75 | KMT2A (0.69) | MAPTALDH1A1HPGDMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | disclosed |
| US-20220332709-A1 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2022-10-20 | — | — | US | disclosed |
| EP-3810606-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2021-04-28 | — | — | EP | disclosed |
| CN-112566910-A | Thiophene derivatives for the treatment of IgE induced diseases | UCB生物制药有限责任公司 | 2021-03-26 | — | — | CN | disclosed |
| WO-2019243550-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332709-A1 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | MAPT 2356/4885ALDH1A1 233/4885HPGD 218/4885 |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | MAPT 2356/4885ALDH1A1 233/4885HPGD 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.